Company Overview - Old National Bancorp is the holding company of Old National Bank, the sixth largest commercial bank headquartered in the Midwest [3] - The company serves clients primarily in the Midwest and Southeast, with approximately $71 billion in assets and $38 billion in assets under management [3] - Old National ranks among the top 25 banking companies in the United States and has a history dating back to 1834 [3] - The company focuses on building long-term partnerships with clients and supporting the communities it serves [3] - In 2025, Old National was recognized as one of "The Civic 50," an honor for the 50 most community-minded companies in the U.S. [3] Upcoming Events - Jim Ryan, Chairman and CEO of Old National Bancorp, will present at the 2025 Barclays Global Financial Services Conference on September 8, 2025, at 2:45 p.m. ET [1] - The presentation will be accessible via a live webcast through the Investor Relations section of the company's website [2] - A replay of the presentation will be available for 180 days after the event for those unable to attend live [2]

Core Insights - Syntec Optics Holdings, Inc. has launched a New York State certified apprenticeship program aimed at developing skilled manufacturing technicians, marking it as the first of its kind in the United States [1][4] Group 1: Program Details - The apprenticeship program was developed in collaboration with the Rochester Technology and Manufacturing Association (RTMA) and Monroe Community College (MCC) to address the talent shortage in the optics and photonics manufacturing sector [2] - The curriculum includes on-the-job training, mentorship, and specialized coursework in nanomachining and optics, designed to provide a strong foundation in this field [3] - The program is supported by the New York State Department of Labor and spans 18 months to 4 years, with participants eligible for funding for education and necessary tools [4][5] Group 2: Strategic Importance - The program is part of Syntec Optics' strategy to drive innovation and rebuild critical manufacturing skills in the U.S., emphasizing the development of future leaders and innovators in optics [5] - The company is experiencing significant demand for its Advanced Manufacturing Platform across various sectors, including Hyperspectral Imaging, Rocket Propulsion, and Biomedical Vision Correction, which necessitates a skilled workforce [5] - Currently, six apprentices are enrolled in the program, which aims to meet the growing customer demand with a highly skilled workforce [5] Group 3: Company Overview - Syntec Optics is a leading manufacturer in the optics and photonics sector, operating for over two decades and providing a competitive advantage through its state-of-the-art facility and diverse product lines [6] - The company continues to expand its offerings, including Low Earth Orbit (LEO) satellite optics and lightweight night vision goggle optics for defense [6]

Core Viewpoint - Rapport Therapeutics is set to announce topline results for the Phase 2a trial of its investigational drug RAP-219, aimed at treating drug-resistant focal onset seizures, during a conference call on September 8, 2025 [1]. Company Overview - Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [3]. - The company’s founders have made significant discoveries regarding receptor associated proteins (RAPs) in the brain, which underpin the RAP technology platform [3]. - The lead investigational drug, RAP-219, is designed to achieve neuroanatomical specificity by selectively targeting a RAP expressed in specific brain regions [3]. - In addition to drug-resistant focal onset seizures, RAP-219 is being explored as a potential treatment for bipolar mania and diabetic peripheral neuropathic pain [3]. - The company is also engaged in preclinical and late-stage discovery programs targeting chronic pain and hearing disorders [3].

Core Insights - Coherent Corp. has joined the Diode Technology Working Group within the STARFIRE Hub, a collaborative initiative aimed at advancing inertial fusion energy (IFE) [1][4] - This collaboration emphasizes Coherent's dedication to innovating in photonics to tackle complex energy challenges and contribute to sustainable fusion energy solutions [2][3] Company Overview - Coherent is recognized as a global leader in photonics, providing technology solutions across various industries including datacenter, communications, and industrial markets [4][5] - The company has been operational since 1971 and has a presence in over 20 countries, showcasing a robust technology stack and supply chain resilience [5] Industry Context - The STARFIRE project, supported by the U.S. Department of Energy, aims to establish a technical foundation for future commercial fusion systems, highlighting the importance of collaboration in the energy sector [4]

Certificate of Amendment Changes Name to FG Nexus Inc.,Increases Authorized Shares, Triggers Conversion of Automatic Exercise Pre-Funded Warrants to Common Stock and Expands Outstanding Share Count to Over 35 million Charlotte, NC, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Fundamental Global Inc. (Nasdaq: FGNX, FGNXP) (the "Company" or "FG Nexus"), announced that its Certificate of Amendment to its amended and restated articles of incorporation has been declared effective by the Nevada Secretary of State today. Pu ...

Core Viewpoint - Artelo Biosciences, Inc. has successfully closed a public offering of common stock and pre-funded warrants, raising approximately $3.0 million to support its clinical-stage pharmaceutical initiatives focused on lipid-signaling pathways for various medical conditions [1][2]. Group 1: Offering Details - The company offered 640,924 shares of common stock at a public price of $4.40 per share and pre-funded warrants to purchase up to 40,894 shares at a price of $4.399 per warrant [1]. - The gross proceeds from the offering were approximately $3.0 million before deducting underwriting discounts and other expenses [2]. - Underwriters were granted a 45-day option to purchase an additional 102,272 shares at the public offering price to cover over-allotments [2]. Group 2: Regulatory and Documentation - The shares and warrants were offered under a "shelf" registration statement on Form S-3, which was filed with the SEC on July 6, 2023, and declared effective on July 14, 2023 [3]. - The final prospectus supplement and accompanying base prospectus were filed with the SEC on September 5, 2025, and are available on the SEC's website [4]. Group 3: Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing therapeutics that modulate lipid-signaling pathways, addressing significant unmet needs in various medical conditions including cancer and pain [7]. - The company has adopted a corporate finance initiative to deploy excess capital into digital assets as part of its treasury strategy [7].

Company Overview - Gyre Therapeutics is a biopharmaceutical company based in San Diego, CA, focused on developing and commercializing Hydronidone for liver fibrosis, including MASH, in the United States [3] - The company leverages its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis [3] - In China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, which includes therapeutic expansions of ETUARY and development programs for F573, F528, and F230 [3] Upcoming Events - Management will present at the H.C. Wainwright 27 Annual Global Investment Conference on September 10, 2025, at 12:30 p.m. ET [1] - A live webcast of the presentation will be available on Gyre's website, with a replay accessible after the live session [2]

MONTEVIDEO, Uruguay, Sept. 05, 2025 (GLOBE NEWSWIRE) -- DLocal Limited (“dLocal”), (NASDAQ:DLO) a technology-first payments platform, today announced the closing of a previously announced secondary offering of 17,250,000 Class A common shares (including 2,250,000 Class A common shares pursuant to the full exercise of the underwriters’ option) by an entity associated with General Atlantic at a price to the public of $12.75 per share. The Company is not selling any Class A common shares in the offering and wi ...

- Genevieve Baer and Ezra Laniado resign from the Board of Directors - SAN DIEGO, CA, Sept. 05, 2025 (GLOBE NEWSWIRE) -- RYVYL Inc. (NASDAQ: RVYL) ("RYVYL” or the "Company") has appointed current CFO George Oliva and Gene Jones to its Board of Directors. Independent directors Genevieve Baer and Ezra Laniado have resigned from the Board of Directors, effective August 31, 2025. George Oliva has served as RYVYL’s CFO since October 2023. He has over 30 years of experience as a senior finance professional, with ...

New York, NY, Sept. 05, 2025 (GLOBE NEWSWIRE) -- GSR IV Acquisition Corp. (NASDAQ: GSRF) (“GSRF” or the “Company”) announced today that it closed its initial public offering of 23,000,000 units at a price of $10.00 per unit, for aggregate gross proceeds of $230,000,000. The offering size reflects the full exercise of the underwriter’s over-allotment option. Each unit consists of one of the Company’s Class A ordinary shares (the “Class A Ordinary Shares”) and one-seventh (1/7th) of one right (the “Rights”), ...